Search results
Showing 1 to 32 of 32 results for alzheimer's disease
NICE research projects and partners.
Find out more about NICE technology appraisals advisory committee D members
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
Health Technology Assessment Innovation Laboratory (HTA Lab)
NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.
treating erythropoietic protoporphyria 30 July 2018 TA111 Alzheimer´s disease - donepezil, rivastigmine, galantamine and...
NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the new class of Alzheimer’s drugs but key issues need to be considered, a new report has found.
Working at the forefront of neurodegenerative disease research
Claire Hawksworth reveals NICE’s role in a global partnership to better understand neurodegenerative conditions and speed up delivery of innovative treatments.
How NICE recommendations are being used to improve outcomes in priority areas of dementia care
NICE's impact on preventing or delaying the onset of dementia
NICE's impact on dementia referral, diagnosis and care planning
NICE's impact on hospital stays, delays in leaving hospital and independent living
A quick and easy-to-read guide for care home managers about achieving good oral health in care homes.
Artificial intelligence for analysing CT brain scans (MIB207)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans .
This quality standard covers preventing dementia, and assessment, management and health and social care support for people with dementia. It describes high-quality care in priority areas for improvement.
View quality statements for QS184Show all sections
Sections for QS184
- Quality statements
- Quality statement 1: Raising awareness – health promotion interventions
- Quality statement 2: Diagnosis
- Quality statement 3: Advance care planning
- Quality statement 4: Coordinating care
- Quality statement 5: Activities to promote wellbeing
- Quality statement 6: Managing distress
- Quality statement 7: Supporting carers
Urinary incontinence and pelvic organ prolapse in women: management (NG123)
This guideline covers assessing and managing urinary incontinence and pelvic organ prolapse in women aged 18 and over. It also covers complications associated with mesh surgery for these conditions.
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)
Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.
Dementia: assessment, management and support for people living with dementia and their carers (NG97)
This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.
This guideline covers oral health, including dental health and daily mouth care, for adults in care homes. The aim is to maintain and improve their oral health and ensure timely access to dental treatment.
intravenous iron preparations in children with anaemia of chronic kidney disease (CKD), including safety, dosing and efficacy outcomes.
This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.
the impact of treating Alzheimer's disease on mortality and institutionalisation, and to assess the relationship between...
data on the effects of treating people with Alzheimer's disease on both short-term and long-term outcomes, disease...
Excess winter deaths and illness and the health risks associated with cold homes (NG6)
This guideline covers reducing the health risks (including preventable deaths) associated with living in a cold home. It aims to improve the health and wellbeing of people vulnerable to the cold. Improving the temperature in homes, by improving energy efficiency, may also help reduce unnecessary fuel consumption.
Physical activity: brief advice for adults in primary care (PH44)
This guideline covers providing brief advice on physical activity to adults in primary care. It aims to improve health and wellbeing by raising awareness of the importance of physical activity and encouraging people to increase or maintain their activity level.
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111)
This guidance has been updated and replaced by NICE technology appraisal 217.
Alzheimer's disease (mild to moderate) - donepezil, rivastigmine and galantamine (TA19)
This guidance has been replaced by NICE technology appraisal guidance 111.
Gantenerumab for treating early Alzheimer's disease TS ID 10668
Awaiting development [GID-TA11072] Expected publication date: TBC
In development [GID-TA11269] Expected publication date: TBC
Hydromethylthionine mesylate for treating Alzheimer's disease TS ID 11890
Awaiting development [GID-TA11379] Expected publication date: TBC
In development [GID-TA11221] Expected publication date: 11 September 2024
In development [GID-TA11220] Expected publication date: 17 July 2024